New Alzheimer's drug lecanemab under close watch in 120-patient study
NCT ID NCT06741553
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This study follows 120 people with early Alzheimer's disease or mild cognitive impairment who are taking lecanemab, a new FDA-approved drug that targets harmful protein clumps in the brain. Researchers will track changes in memory, daily function, and brain scans over 18 months. They also watch for side effects like brain swelling or small bleeds. The goal is to see how well the drug works and who might be at higher risk for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.